Ask AI
BsAb Challenge

CE / CME

Individualizing Therapy for Relapsed/Refractory Multiple Myeloma: Bispecific Antibody Therapy

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: December 31, 2025

Expiration: June 30, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

You are treating a patient with a BCMA bispecific antibody (BsAb) who is experiencing a fever 2 months after treatment initiation.

2.

In shared decision-making, which of the following BsAbs would you recommend for a patient with relapsed/refractory (R/R) multiple myeloma (MM) who prefers subcutaneous dosing and would like to avoid changes in taste (dysgeusia) as a drug-related toxicity?